Platelets in health and disease: Platelet GPIIb-IIIa structure and function: Recent advances in antiplatelet therapy

Drugs of the Future

Volumn 21, Issue 11, 1996, Pages 1141-1154

  Mousa, S A ^a   Bennett, J S ^b  

^a DUPONT COMPANY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 AMIDINOBENZOYLGLYCYL) 3 METHOXYCARBONYLMETHYL 2 OXO 1 PIPERAZINEACETIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; HEPARIN; LAMIFIBAN; LEFRADAFIBAN; LOTRAFIBAN; N [(4 METHYLPHENYL)SULFONYL] 3 [[[5,6,7,8 TETRAHYDRO 4 OXO 5 [2 (4 PIPERIDINYL)ETHYL] 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 2 YL]CARBONYL]AMINO]ALANINE; RO 43 5054; S 1197; S 1762; SB 208651; SC 57345; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

ANGINA PECTORIS; ATHEROSCLEROSIS; BLEEDING; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; REVIEW; RISK FACTOR; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0030455738     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Hirsh, P.D., Hillis, L.D., Campbell, W.B., Firth, E.G., Willerson, J T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. New Engl J Med 1981, 304: 685-91.
2. Rubenstein, M.D., Wall, R.T., Bain, D.S., Harrison, D.C. Platelet activation in clinical coronary artery disease and spasm. Am Heart J 1981, 102: 363-7.
3. Smitherman, T.C., Milam, M., Woo, J., Willerson, J.T., Frenkel, E.P. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: Direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol 1981, 48: 395-402.
4. Fitzgerald, D.J., Roy, L., Catella, F., Fitzgerald, G.A. Platelet activation in unstable coronary disease. New Engl J Med 1986, 315: 983-9.
5. Fuster, V., Steele, P.M., Chesebro, J.H. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol 1985, 5: 175-84B.
6. Travis, J. Biotech gets a grip on cell adhesion: Frontier in biotechnology. Science 1993, 260: 906-8.
7. Willerson, J.T., Golino, P., Eidt, J., Campbell, W.B., Buja, L.M. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989, 198-205.
8. Davies, M.J., Thomas, A.C. Plaque fissuring - The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985, 53: 363-73.
9. Hamm, C.W., Bliefield, W., Kupper, W., Lorenz, R.L., Weber, P.C., Wober, W. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987, 10: 998-1004.
10. Ashby, B., Daniel, J.L., Smith, J.B. Mechanisms of platelet activation and inhibition. Platelet Health Dis 1990, 4 (1): 1-26.
11. Saltiel, E., Ward, A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states. Drugs 1987, 34: 222-62.
12. Mousa, S., Bozarth, J., Forsythe, M., Pease, L., Reilly, T.M. Role of platelet GPIIb-IIIa receptors in the modulation of platelet plasminogen activator inhibitor type-1 (PAI-1 release). Life Sci 1994, 54 (16): 1155-62.
13. Walenga, J.M., Pifarra, R., Fareed, J. Recombinant hirudin as an antithrombotic agent. Drugs Fut 1990, 15 (3): 267-70.
14. Weiss, H.J., Lages, B. The response of platelets to epinephrine in storage pool deficiency - Evidence pertaining to the role of adenosine diphosphate in mediating primary and secondary aggregation. Blood 1988, 72: 1717-25.
15. Pytela, R., Pierschbacher, M.S., Ginsberg, M.H., Plow, E.F., Ruoslahti, E. Platelet membrane glycoprotein IIb/IIIa: Member of a family of RGD specific adhesion receptors. Science 1986, 231: 1559-62.
16. Philips, D.R., Charo, I.F., Scarborough, R.M. GPIIb-IIIa: The responsive integrin. Cell 1991, 65: 359-62.
17. D'Souza, S.E., Ginsberg, M.H., Burke, T.A., Plow, E.F The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of its a subunit. J Biol Chem 1990, 265: 3440-6.
18. Weiss, H.J., Hawiger, J., Ruggeri, Z.M., Turitto, V.T., Thiagarajan, P., Hoffmann, T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest 1989, 83: 288-97.
19. Kloczewiak, M., Timmons, S., Lukas, T.J., Hawiger, J. Platelet receptor recognition site on human fibrinogen: Synthesis and structure-function relationship of peptides corresponding to the carboxyterminal segment of the gamma chain. Biochemistry 1984, 23: 1757-74.
20. Plow, E.F., Pierschbacher, M.D., Ruoslahti, E., Marguerie, G., Ginsberg, M.H. Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets. Blood 1987, 70: 110-5.
21. 2 as an antiaggregatory agent in the dog by intracoronary administration. Thromb Haemost 1989, 61: 183-8.
22. Bennett, J.S., Valaire, G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979, 64: 1393-401.
23. Mousa, S., Hassell, S., Pierce, S. et al. Intravenous antiplatelet efficacy and safety of the platelet GPIIb-IIIa antagonist, DMP728 in anesthetized dogs. Thromb Res 1994, 76 (2): 109-19.
24. Ruggeri, Z.M., Houghton, R.A., Russel, S.R., Zimmerman, T.S. Inhibition of platelet function with synthetic peptide designed to be high affinity antagonist of fibrinogen binding to platelets. Proc Natl Acad Sci USA 1986, 83: 5708-12.
25. Nicholson, N.S., Panzer-Knodle, S.G., Salyers, A.K. et al. In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent. Thromb Res 1991, 62: 567-78.
26. Nichols, A.J., Ruffolo, R.R., Huffman, W.F., Poste, G., Samanen, J. Development of GPIIb-IIIa antagonists as antithrombotic drugs. Trends Pharmacol Sci 1992, 13 (11): 413-7.
27. Yasuda, T., Gold, H.K., Fallon, J.T. et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988, 81: 1284-91.
28. Coller, B.S., Folis, J.D., Scudder, L.E., Smith, S.R. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIia receptor in an experimental animal model. Blood 1986, 68: 783-6.
29. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa, in patient with unstable angina pectoris. J Clin Invest 1990, 86: 651-9.
30. Hartman, G.D., Egbertson, M.S., Halczenko, W. et al. Non-peptide fibrinogen receptor antagonists: I. Discovery and design of exosite inhibitors. J Med Chem 1992, 36: 4640-2.
31. Lu, H.R., Gold, H.K., Wu, Z. et al. G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial aversion graft recanalization with recombinant tissue-type plasminogen activator in dogs. Thromb Haemost 1992, 67: 686-9.
32. Collen, D., Lu, H.R., Stassen, J-M. et al. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb-IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost 1994, 71: 95-102.
33. Peerlinck, K., De Lepeleire, I., Goldberg, M. et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993, 88: 1512-7.
34. Nicholson, N.S., Panzer-Knodle, S.G., Salyers, A.K. et al. SC-54684:An orally active inhibitor of platelet aggregation. Circulation 1995, 91: 403-10.
35. Szalony, J., Haas, N., Salyers, A. et al. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation 1995, 91: 411-6.
36. Bizzozero, J. Uber einer neuen Formbestandtheil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung. Virchows Arch 1882, 90: 261-332.
37. Born, G.V.R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 194: 927-9.
38. Charo, I.F., Feinman, R.D., Detwiler,T.C. Interrelations of platelet aggregation and secretion. J Clin Invest 1977, 60: 866-73.
39. Jaffe, R., Deykin, D. Evidence for a structural requirement for the aggregation of platelets by collagen. J Clin Invest 1974, 53: 875-83.
40. Feinman, R.D., Lubowsky, J., Charo, I., Zabinski, M.P. The lumiaggregometer: A new instrument for simultaneous measurement of secretion and aggregation by platelets. J Lab Clin Med 1977, 90: 125-9.
41. Ingerman-Wojenski, C., Smith, J.B., Silver, M.J. Evaluation of electrical aggregometry: Comparison with optical aggregometry, secretion of ATP, and accumulation of radiolabeled platelets. J Lab Clin Med 1983, 101: 44-52.
42. Gear, A.R.L. Reduction in single platelets during primary and secondary aggregation. Thromb Haemost 1981, 45: 298.
43. Sixma, J.J., Wester, J. The hemostatic plug. Semin Hematol 1977, 14: 265-99.
44. Turrito, V.T., Weiss, H.J., Zimmerman, T.S., Sussman, I.I. Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion. Blood 1985, 65: 823-31.
45. Ruggeri, Z.M., DeMarco, L., Gatti, L., Bader, R., Montgomery, R.R. Platelets have more than one binding site for von Willebrand factor. J Clin Invest 1983, 72: 1-12.
46. Ruggeri, Z.M., Bader, R., DeMarco, L. Glanzmann thrombasthenia: Deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci USA 1982, 79: 6038-41.
47. Alevriadou, B.R., Moake, J.L., Turner, N.A. et al. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993, 81: 1263-76.
48. Lopez, J.A. The platelet glycoprotein Ib-IX complex. Blood Coagul Fibrino 1994, 5: 97-119.
49. Andrews, R.K., Fox, J.E.B. Interaction of purified actin-binding protein with the platelet membrane glycoprotein Ib-IX complex. J Biol Chem 1991, 266: 7144-7.
50. Fox, J.E.B., Aggerbeck, L.P., Berndt, M.C. Structure of the glycoprotein Ib-IX complex from platelet membranes. J Biol Chem 1988, 263: 4882-90.
51. Howard, M.A., Firkin, B.G. Ristocetin - A new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971, 26: 362-9.
52. Andrews, R.K., Booth, W.J., Gorman, J.J., Castaldi, P.A., Berndt, M.C. Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human glycoprotein Ib-IX complex. Biochemistry 1989, 28: 8317-26.
53. Roth, G.J. Developing relationships: Arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. Blood 1991, 77: 5-19.
54. O,Toole, T.E., Katagiri, Y., Faull, R.J. et al. Integrin cytoplasmic domains mediate inside-out signal transduction. J Cell Biol 1994, 124: 1047-59.
55. Sims, P.J., Ginsberg, M.H., Plow, E.F., Shattil, S.J. Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex. J Biol Chem 1991, 266: 7345-52.
56. Brass, L.F., Manning, D.R., Shattil, S.J. GTP-binding proteins and platelet activation. Prog Hemost Thromb 1990, 10: 127-74.
57. Wilson, D.B., Neufeld, E.J., Majerus, P.W. Phosphoinositide interconversion in thrombin-stimulated human platelets. J Biol Chem 1985, 260: 1046-51.
58. 2+ mobilization and granule secretion in platelets. J Biol Chem 1985, 260: 15172-9.
59. Exton, J.H. Signaling through phosphatidylcholine breakdown. J Biol Chem 1990, 265: 1-4.
60. Shattil, S.J., Brass, L.F. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem 1987, 262: 992-1000.
61. Hillery, C.A., Smyth, S.S., Parise, L.V. Phosphorylation of human platelet glycoprotein IIIa (GPIIIa). Dissociation from fibrinogen receptor activation and phosphorylation of GPIIIa in vitro. J Biol Chem 1991, 266: 14663-9.
62. Clark, E.A., Shattil, S.J., Brugge, U.S. Regulation of protein tyrosine kinases in platelets. Trends Biochem Sci 1994, 19: 464-9.
63. Phillips, D.R., Charo, I.F., Parise, L.V., Fitzgerald, L.A. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988, 71: 831-43.
64. Bennett, J.S. Structural biology of glycoprotein IIb-IIIa. Trends Cardiovasc Med 1996, 16: 31-6.
65. Weisel, J.W., Nagaswami, C., Vilaire, G., Bennett, J.S. Examination of the platelet membrane glycoprotein IIb/IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem 1992, 267: 16637-43.
66. Hynes, R.O. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1991, 69:11-25.
67. 4 integrinsin vivo. J Clin Invest 1994, 94: 1722-8.
68. Farrell, D.H., Thiagarajan, P., Chung, D.W., Davie, E.W. Role of fibrinogen α and γ chain sites in platelet aggregation. Proc Natl Acad Sci USA 1992, 89: 10729-32.
69. Gartner, T.K., Bennett, J.S. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J Biol Chem 1985, 260: 11891-4.
70. D'Souza, S.E., Ginsberg, M.H., Burke, TA., Lam, S.C-T., Plow, E.F. Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor. Science 1988, 242: 91-3.
71. Lefkovits, J., Plow, E., Topol, E. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. New Engl J Med 1995, 332: 1553-9.
72. Bennett, J.S., Shattil, S.J., Power, J.W., Gartner, T.K. Interaction of fibrinogen with its platelet receptor. Differential effects of a and γ chain fibrinogen peptides on the glycoprotein IIb-IIIa complex. J Biol Chem 1988, 263: 12948-53.
73. Glanzmann, E. Hereditare hamorrhagische Thrombasthenie. Ein Beitrag zur pathologie dur blutplattchen. J Kinderkr 1918, 88: 1-42.
74. Phillips, D.R., Agin, P.P. Platelet membrane defects in Glanzmann's thrombasthenia. J Clin Invest 1977, 60: 535-45.
75. Sosnoski, D.M., Emanuel, B.S., Hawkins, A.L. et al. Chromosomal localization of the genes for the vitronectin and fibronectin receptors a. subunits and for platelet glycoproteins IIb and IIIa. J Clin Invest 1988, 81: 1993-8.
76. Bray, P.R., Barsh, G., Rose, J-P., Luo, X.Y., Magenis, E., Shuman, M.A. Physical linkage of the genes for platelet membrane glycoproteins IIb and IIIa. Proc Natl Acad Sci USA 1988, 85: 8683-7.
77. Kolodziej, M.A., Vilaire, G., Rifat, S., Poncz, M., Bennett, J.S. Effect of deletion of glycoprotein IIb exon 28 on the expression of the platelet glycoprotein IIb/IIIa complex. Blood 1991,78: 2344-53.
78. Poncz, M., Salahandrin, R., Coller, B.S. et al. Glanzmann thrombasthenia secondary to a Gly273→Asp mutation adjacent to the first calcium-binding domain of platelet glycoprotein IIb. J Clin Invest 1994, 93:172-9.
79. Wilcox, D.A., Paddock, C.M., Lyman, S., Gill, J.C., Newman, P.J. Glanzmann thrombasthenia resulting from a single amino acid substitution between the second and third calcium-binding domains of GPIIb. Role of the GPIIb amino terminus in integrin subunit association. J Clin Invest 1995, 95:1553-60.
80. 3 integrin complex. J Biol Chem 1994, 269: 4450-7.
81. 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science 1990, 249: 915-8.
82. 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proc Natl Acad Sci USA 1992, 89: 10169-73.
83. George, J.N., Caen, J.P., Nurden, A.T. Glanzmann's thrombasthenia: The spectrum of clinical disease. Blood 1990, 75: 1383-95.
84. 2 fragments of a monoclonal antibody. Blood 1985, 66: 1456-0.
85. Mousa, S., Forsythe, M., Diemer, M., Thoolen, M., Reilly, T. Thrombolytic antithrombotic, efficacy of the platelet GPIIb-IIIa antagonist DMP728. Coron Artery Dis 1994, 5 (11): 919-27.
86. Tcheng, J.E., Ellis, S.G., George, B.S. et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994, 90: 1757-64.
87. Kleiman, N.S., Ohman, E., Califf, R.M. et al. Profound inhibition of platelet aggregation with monoclonal antibody 73E Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study J Am Coll Cardiol 1993, 22: 381-9.
88. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New Ergl J Med 1994, 330: 956-61.
89. Topol, E.J., Califf, R.M., Weisman, H.F. et al. Radomised trial of coronary intervention with antibody against platelet GPIIb-IIIa integrin for reduction of clinical restenosis: Results at 6 months. Lancet 1994, 343: 881-6.
90. Simoons, M.L., de Boer, M.J., Van den Brand, M. et al. Randomized trial of IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994, 89: 596-603.
91. Simpfendorfer, C., Kottke-Marchant, K., Topol, E.J. First experience with chronic platelet GPIIb-IIIa receptor blockade: A pilot study of xemlofiban an orally active antagonist in unstable angina patients eligible for PTCA. J Am Coll Cardiol 1996, 27 (Suppl A): Abst 242A.
92. Weisenberger, N.H., Muller, T.H., Deichsel, G., Krause, J. Tolerability and platelet fibrinogen receptor occupancy (FRO) after oral treatment with BIBU 104 XX in healthy volunteers. Thromb Haemost 1995, 73 (6): Abst 1315.
93. Barrett, J., Edwards, S., Harris, T. et al. The development of a technetium-99m agent for imaging deep vein thrombosis. In: Technetium & Rhenium in Chemistry and Nuclear Medicine. M. Nicolini et al. (Eds.). 1995, 275-80.
94. Mousa, S., Bozarth, J., Forsythe, M. et al. Antiplatelet, antithrombotic efficacy of DMP728, a novel platelet GPIIb-IIIa receptor antagonist. Circulation 1994, 89: 3-12.
95. Mousa, S.A., Reilly, T.M. Antiplatelet effects of direct acting thrombin inhibitors and platelet GPIIb-IIIa antagonists: Comparative analysis. In: Cardiovascular Disease, 2. Gallo, L.L. (Ed.). Plenum Press: New York 1995, 255-68.
96. 2. J Cardiovasc Pharmacol 1993, 23: 194-202.
97. Rote, W., Mu, D-X., Bates, E.R., Nedelman, M.A., Lucchesi, B.R. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin. J Cardiovasc Pharmacol 1993, 23: 203-11.
98. Théroux, P., Waters, D., Lam, J., Junean, M., McCans, J. Reactivation of unstable angina after discontinuation of heparin. New Engl J Med 1992; 327: 141-5.
99. Gold, H.K., Torres, F.W., Garabedian, H.D. et al. Evidence of a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patient with unstable angina. J Am Coll Cardiol 1993, 21: 1039-47.
100. Nichols, A.J., Ruffolo, R.R., Huffman, W.F., Poste, G., Samanen, J. Development of GPIIb-IIIa antagonists as antithrombotic drugs. Trends Pharmacol Sci 1992, 13 (11): 413-7.
101. Nicolini, F.A., Rios, G., Lee, P., Kottke-Marchant, K., Topol, E.J. Inhibition of thrombin activity alone does not decrease the reocclusion rate following rt-PA-induced thrombolysis in canine coronary artery thrombosis. Thromb Haemost 1993, 69: 992.
102. Clarke, R.J., Mayo, G., Fitzgerald, G.A., Fitzgerald, D.J. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991, 83: 1510-8.
103. Yasuda, T., Gold, H.K., Yaoita, H. et al. Comparison effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990, 16: 714-22.
104. Cook, N.S., Kottirsch, G., Zerwes, H-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs Fut 1994, 19: 135-59.
105. Anderson, H.V., Kirkheeide, R.L., Krishnaswami, A. et al. Cyclic flow variations after coronary angioplasty in humans: Clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol 1994, 23: 1031-7.
106. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990, 86: 651-9.
107. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New Engl J Med 1994, 330: 956-61.
108. Jones, C.R., Ambras, R.J., Rapold, H.J. et al. Ro44-9883: A novel non-peptide GPIIb-IIIa antagonist in man. Thromb Haemost 1993, 69: Abst 560.
109. Théroux, P., Kouz, S., Knudtson, M.L., Kells, C., Nasmith, J.R. A randomized double-blind controlled trial with the non-peptide platelet GPIIb-IIIa antagonist Ro 44-9883 in unstable angina. Circulation 1994, 90: Abst 1-232.
110. Horrigan, M.C., Tcheng, J.E., Califf, R.M. et al. Maximal benefit of Integrelin platelet GPIIb-IIIa blockade 6-24 hours after therapy: Results of the IMPACT-II trial. J Am Coll Cardiol 1996, 27: 536-42.
111. Bernardi, M.M., Califf, P.M., Kleiman, N. et al. Prolonged bleeding times do not predict hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. Circulation 1992, 86(Suppl. I): Abst I-260.
112. Ellis, S.G., Tcheng, J.E., Navetta, F.I. et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coron Artery Dis 1993, 4: 167-75.